NCT04646993|Completed
WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?
WHITE
Which Decision After a First Venous Thromboembolism? The WHITE Study
Loading search results
WHITE
Which Decision After a First Venous Thromboembolism? The WHITE Study
Sponsor study identifier
observational
1,200
1 country
1
Study Start
February 1, 2018
Actual (reported)Primary Completion
December 30, 2021
Actual (reported)Study Completion
February 28, 2022
Actual (reported)The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of anticoagulation after a first-ever episode of venous thromboembolism (VTE) The general aim of the study is to evaluate the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulant therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2018
Actual (reported)November 18, 2020
Actual (reported)November 30, 2020
Actual (reported)December 30, 2021
Actual (reported)February 28, 2022
Actual (reported)Number of patients who continue or stop the anticoagulant treatment
Registration of number of patients who continue or stop the treatment; registration of type reasons guiding the attending physician's decision on the management of secondary prevention (eg: Bleeding score, laboratory test, presence of residual vein trombosis, risk or recurrence)
From the end of the 3rd month to the end of 12th month of anticoagulant treatment
Frequence of adverse events during follow-up
Frome the first day of enrollment up to 24 monhts
All patients of any ethnicity having had a first-ever event of provoked or unprovoked DVT of the lower limbs and/or PE given maintenance anticoagulants (NOACs, VKAs, or LMWHs) according to the local procedures (usually for 3 to 12 months) and to be re-evaluated to decide the treatment to be prescribed after such period by the attending physicians
Clinical Trial Centre, MATMED
Hodonín, 695 01, Czechia
Jiří Matuška, Prof
Clinical Trial Centre, Hodonin, Czech Republic
1,200 participants (actual enrollment reported by the registry).
First Submitted
November 18, 2020
First Posted
November 30, 2020
Study Start
February 1, 2018
Actual (reported)Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
Contact the study team to confirm eligibility.
Primary Completion
December 30, 2021
Actual (reported)Study Completion
February 28, 2022
Actual (reported)Last Updated
March 11, 2022
Record last verified: 2021-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: